全文获取类型
收费全文 | 128975篇 |
免费 | 5459篇 |
国内免费 | 301篇 |
专业分类
耳鼻咽喉 | 2015篇 |
儿科学 | 4142篇 |
妇产科学 | 2690篇 |
基础医学 | 17332篇 |
口腔科学 | 4376篇 |
临床医学 | 7892篇 |
内科学 | 32000篇 |
皮肤病学 | 4084篇 |
神经病学 | 10028篇 |
特种医学 | 3375篇 |
外国民族医学 | 1篇 |
外科学 | 15903篇 |
综合类 | 697篇 |
一般理论 | 36篇 |
预防医学 | 12428篇 |
眼科学 | 2871篇 |
药学 | 8727篇 |
中国医学 | 619篇 |
肿瘤学 | 5519篇 |
出版年
2023年 | 803篇 |
2022年 | 496篇 |
2021年 | 2556篇 |
2020年 | 1278篇 |
2019年 | 2869篇 |
2018年 | 4984篇 |
2017年 | 2897篇 |
2016年 | 2696篇 |
2015年 | 3010篇 |
2014年 | 3390篇 |
2013年 | 5188篇 |
2012年 | 9178篇 |
2011年 | 9832篇 |
2010年 | 4945篇 |
2009年 | 3443篇 |
2008年 | 7841篇 |
2007年 | 8394篇 |
2006年 | 7790篇 |
2005年 | 7714篇 |
2004年 | 6833篇 |
2003年 | 6421篇 |
2002年 | 6027篇 |
2001年 | 3846篇 |
2000年 | 4489篇 |
1999年 | 3323篇 |
1998年 | 638篇 |
1997年 | 432篇 |
1996年 | 437篇 |
1995年 | 339篇 |
1994年 | 256篇 |
1993年 | 251篇 |
1992年 | 1283篇 |
1991年 | 1073篇 |
1990年 | 945篇 |
1989年 | 821篇 |
1988年 | 679篇 |
1987年 | 670篇 |
1986年 | 663篇 |
1985年 | 573篇 |
1984年 | 412篇 |
1983年 | 328篇 |
1979年 | 346篇 |
1975年 | 291篇 |
1974年 | 316篇 |
1973年 | 350篇 |
1972年 | 292篇 |
1971年 | 315篇 |
1970年 | 292篇 |
1969年 | 292篇 |
1968年 | 267篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Carlos García-Girón Andrés García Palomo Carmen Alonso López Ángel León Carbonero Miguel Méndez Urena Encarna Adróver Cebrián Ramón Barceló Galíndez Mónica Arroyo Yustos José Álvarez Gallego 《Clinical & translational oncology》2005,7(6):244-249
Introduction This phase II study investigated the anti-tumour activity and toxicity of CPT-11 (250 mg/m2 i.v. infusion over 60 minutes)
administered every 2 weeks as second-line chemotherapy in patients with advanced colorectal cancer (CRC).
Material and methods Patients (n=63) with histology diagnosis of advanced CRC and proven resistance to previous fluoropyrimidine therapy were enrolled.
Results A total of 510 CPT-11 cycles were administered, with a mean of 8 cycles per patient (range: 1–32). The median relative dose
intensity was 93%. Partial response (PR) was obtained in 11 patients (17.5%; 95%CI: 8.1%–26.7%) and 29 patients (46.0%) showed
stable disease (clinical benefit of 63.5%). The median duration of response was 6.8 months (95%CI: 6.1–7.5 months), median
survival was 8.8 months (95%CI: 6.3–11.5 months) and median time to disease progression was 4.5 months (95%CI: 3.9–5.0 months).
Overall, this schedule of CPT-11 chemotherapy was well tolerated by the patient. Neutropenia was the most frequent grade 3/4
haematological toxicity (20.6% of patients and 4.1% of cycles). Neutropenia with concurrent fever or infection occurred in
7 patients (11.1%). Late onset diarrhoea was the most frequent grade 3/4 non-haematological toxicity (19.0% of patients and
2.3% of cycles). Other, lower-incidence, toxicities were anaemia, fever, infection, mucositis, nausea and vomiting. There
were no toxic deaths.
Conclusions We found that CPT-11, administered as 250 mg/m2 i.v. infusion over 60 minutes every 2 weeks, was active and well tolerated schedule in the second-line chemotherapy of advanced
CRC patients. This bi-weekly scheme could be used as an alternative to the weekly or the every-three-week schedule as well
as in combined therapies with other chemotherapeutic agents for the treatment of advanced, metastatic, CRC. 相似文献
992.
993.
Sonia Maciá Escalante Carmen Guillén Ponce Ma José Molina Garrido Ma José Martínez Ortiz Inmaculada Ballester Navarro Alfredo Carrato Mena 《Clinical & translational oncology》2005,7(9):414-416
Prognosis in prostate cancer is determined, in greater part, by the presence of metastases. Bone metastases can occur in any part of the skeleton even, for example, at the base of the skull. We present a case of a 78 year old male who, in December 2001, presented with paralysis of the third cranial nerve. The NMR and CAT scans were normal and circulating levels of PSA were elevated. He was referred to the Urology Service where the treatment guidelines included complete androgen block. Subsequently, he developed retro-orbital pain, divergent strabismus and palpebral ptosis. CAT and NMR indicated a soft tissue mass at the sphenoid level. Treatment was Gamma Knife Radio-surgery. Since August 2004, in conjunction with the latest rise in PSA, the patient's general status deteriorated considerably and he was referred to the Oncology Service. there was an increase in the paralysis of the third, fourth and sixth cranial nerve (complete left ophthalmoplegia) and left-central facial paralysis. Metastases from prostate cancer can be disseminated via the lymphatic or the blood system. Currently, there are more metastases from large-size tumours. Metastases are critical in prostate cancer because of their adverse effect on the patient's survival. Measurements of circulating levels of prostate specific antigen and prostate acid phosphatase are very useful in the clinical diagnosis of the primary tumour, or its metastases. 相似文献
994.
Ana Lucas Calduch María Dolores Arnaiz Fernández Sol San José Maderuelo Valentí Navarro Pérez Gala Serrano Bermúdez Ana Montes Borinaga Felipe Cardenal Alemany Branislav Jeremic Ferran Guedea Edo 《Clinical & translational oncology》2005,7(7):314-320
Purpose We retrospectively reviewed our institution’s database to investigate the outcome and impact of combined radiochemotherapy
(RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).
Material and methods Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered
concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation
(PCI).
Results Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered
to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall
survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent
CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local
recurrence, as was additional PCI for distant metastasis-free survival.
Conclusions Our results are similar to those reported previously in the literature. The main point of interest is that our patients were
non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature.
相似文献
995.
María Velasco Latrás Luis Carreras Coderch Fernando Antoñanzas Villar Juan Coya Viña José Martín Comín Francisco Martínez Carderón José Nieto Martín-Bejarano Alberto Sáenz Cusí Gala Serrano Bermúdez Amaya Echevarría Icaza 《Clinical & translational oncology》2005,7(5):198-204
Objective. To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet®) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases. Method. A decision tree model for the treatment of bone pain due to metastases was adapted to the Spanish context. The model represents the standard treatment patterns in Spain for the study population. The time-course of the model is 4 months and it computes an estimate for the cost of pain control per patient. The effectiveness data for the model derive from a randomised trial. The current treatment patterns have been established according to the consensus opinions of a group of medical experts. Results. The cost of pain control per patient is ? 12,515.39 for conventional therapy and ? 5,595.52 for samarium-153 (Quadramet®) therapy. The incremental cost-effectiveness analysis shows that samarium-153 (Quadramet®) is a dominant therapy. It presents lower costs and higher efficacy than the conventional strategy. The sensitivity analyses showed these results to be robust. Conclusion. Samarium-153 (Quadramet®) is costeffective in treating pain in patients with prostate cancer and bone metastases. 相似文献
996.
Isabel Monteiro-Grillo Pedro Marques-Vidal Marília Jorge 《Clinical & translational oncology》2005,7(11):499-503
Purpose To compare the quality-of-life (QoL) and psycho-social changes in a group of patients with early breast cancer who underwent
conservative surgery (BCS) or modified radical mastectomy (MRM).
Methods Self-administered questionnaire assessing body image perception, social habits, sexual attraction and self-consciousness with
relatives/friends, was randomly assigned to 125 patients (61 BCS, 64 MRM; aged 53±8 and 50±9 years, respectively, p=NS).
Results MRM patients reported a significantly higher frequency of changes in body image perception and other related social behaviour
such as avoiding going to the beach or using low-cut clothes, and reticence with friends. Conversely, no differences were
found regarding sexuality, denial of the disease by the husband/partner, or concealing the disease from family members. Also,
no significant differences were found between patients above and below the age of 50 years, for all variables studied after
adjustment for surgical procedure.
Conclusions Modified radical mastectomy has a negative effect on body image perception and in social behaviour patterns of patients and
with a concomitant decrease in QoL. The sexuality of the patient is not significantly affected. 相似文献
997.
998.
Fernando Moreno Antón Javier Sastre Valera Belén Loboff de León Sara López-Tarruella Luis Ortega Medina Eduardo Díaz-Rubio 《Clinical & translational oncology》2005,7(7):321-323
Metastastic tumours involving the epididymis are rare and most often found in patients with disseminated disease. It is even more unusual when the metastasis of the epididymis is the first sign of tumour recurrence. We report a case of an asymptomatic recurrent colon carcinoma presenting as metastasis in the epididymis. Although metastatic cancer presenting as an intra-scrotal mass is extremely rare, it should be considered as a possibility in patients who present with a mass involving the testicle or epididymis. 相似文献
999.
1000.
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. 总被引:2,自引:0,他引:2
Emiliano Honrado Ana Osorio José Palacios Roger L Milne Lydia Sánchez Orland Díez Alicia Cazorla Kirsi Syrjakoski David Huntsman P?ivi Heikkil? Enrique Lerma Anne Kallioniemi Carmen Rivas William D Foulkes Heli Nevanlinna Javier Benítez 《Journal of clinical oncology》2005,23(30):7503-7511
PURPOSE: Morphologic and immunohistochemical studies of familial breast cancers have identified specific characteristics associated with BRCA1 mutation-associated tumors when compared with BRCA2 and non-BRCA1/2 tumors, but have not identified differences between BRCA2 and non-BRCA1/2 tumors. Because BRCA1 and BRCA2 genes participate in the DNA repair pathway, we have performed an immunohistochemical study with markers related to this pathway to establish the profile of the three groups. MATERIALS AND METHODS: We have studied two tissue microarrays that include 103 familial and 104 sporadic breast tumors, with a panel of DNA repair markers including ATM, CHEK2, RAD51, RAD50, XRCC3, and proliferating cell nuclear antigen. RESULTS: We found more frequent expression of CHEK2 in BRCA1 and BRCA2 tumors than in non-BRCA1/2 and sporadic tumors. We found absence of nuclear expression and presence of cytoplasmic expression of RAD51 in BRCA2 tumors that differentiate them from other familial tumors. We validated these results with a new series of patient cases. The final study with 253 familial patient cases (74 BRCA1, 71 BRCA2, 108 non-BRCA1/2), and 288 sporadic patient cases, has allowed us to confirm our preliminary results. Because BRCA2 tumors present a specific immunohistochemical profile for RAD51 and CHEK2 markers that is different from non-BRCA1/2 tumors, we have built a multivariate model with these markers that distinguish both tumors with an estimated probability of at least 76%. CONCLUSION: Our results suggest that BRCA2 tumors demonstrate more cytoplasmic and less nuclear RAD51 staining, and increased CHEK2 staining. This pattern may distinguish BRCA2 from familial non-BRCA1/2 tumors. 相似文献